Rye Brook Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Rye Brook Capital’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.36M	Buy	+67,330	New	+$6.97M	5.16%	5

Other funds holding PPH

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

WT Wealth Management Scottsdale, Arizona $361M AUM 23.03% 1-Year Est. Return

Fluent Financial Dallas, Texas $280M AUM 16.1% 1-Year Est. Return

AAFMAA Wealth Management & Trust Fayetteville, North Carolina $286M AUM 19.57% 1-Year Est. Return

Cassady Wealth & Retirement Planning Henderson, Nevada $215M AUM

Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return

ARQ Wealth Advisors Scottsdale, Arizona $807M AUM 19.58% 1-Year Est. Return

Warner Financial Bethesda, Maryland $340M AUM 22.81% 1-Year Est. Return

Telos Capital Management San Diego, California $1.13B AUM 27.95% 1-Year Est. Return

Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

Rye Brook Capital's PPH Position: Q2 2026 in Review

Rye Brook Capital opened a new position in VanEck Pharmaceutical ETF (PPH) in Q2 2026: 67,330 shares worth $7.36M. The stake represents 5.16% of the portfolio and ranks #5 among its holdings.

31 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Rye Brook Capital held 67,330 shares of VanEck Pharmaceutical ETF worth $7.36M as of Q2 2026.
VanEck Pharmaceutical ETF was a new Rye Brook Capital position in Q2 2026.
VanEck Pharmaceutical ETF made up 5.16% of Rye Brook Capital's portfolio in Q2 2026, its #5 holding.
31 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Rye Brook Capital's 13F filing for Q2 2026, filed 20 Jul 2026.